Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CytomX Therapeutics (CTMX) EBT: 2013-2024

Historic EBT for CytomX Therapeutics (CTMX) over the last 12 years, with Dec 2024 value amounting to $32.1 million.

  • CytomX Therapeutics' EBT fell 344.45% to -$14.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.3 million, marking a year-over-year increase of 87.67%. This contributed to the annual value of $32.1 million for FY2024, which is 865.78% up from last year.
  • Per CytomX Therapeutics' latest filing, its EBT stood at $32.1 million for FY2024, which was up 865.78% from $3.3 million recorded in FY2023.
  • In the past 5 years, CytomX Therapeutics' EBT registered a high of $32.1 million during FY2024, and its lowest value of -$115.9 million during FY2021.
  • Moreover, its 3-year median value for EBT was $3.3 million (2023), whereas its average is -$21.3 million.
  • Per our database at Business Quant, CytomX Therapeutics' EBT plummeted by 47.17% in 2021 and then surged by 865.78% in 2024.
  • Over the past 5 years, CytomX Therapeutics' EBT (Yearly) stood at -$78.7 million in 2020, then crashed by 47.17% to -$115.9 million in 2021, then climbed by 14.29% to -$99.3 million in 2022, then soared by 103.35% to $3.3 million in 2023, then skyrocketed by 865.78% to $32.1 million in 2024.